Identification of differentially expressed genes in uveal melanoma using suppressive subtractive hybridization

Solange Landreville, Caroline B. Lupien, Francois Vigneault, Manon Gaudreault, Mélissa Mathieu, Alain P. Rousseau, Sylvain L. Guérin, Christian Salesse

LOEX/CUO recherche, Centre hospitalier affilié universitaire de Québec, Hôpital du Saint-Sacrement, and Département d’ophthalmologie, Faculté de médecine, Université Laval, Québec, Québec, Canada

Purpose: Uveal melanoma (UM) is the most common primary cancer of the eye, resulting not only in vision loss, but also in metastatic death. This study attempts to identify changes in the patterns of gene expression that lead to malignant transformation and proliferation of normal uveal melanocytes (UVM) using the Suppressive Subtractive Hybridization (SSH) technique.

Methods: The SSH technique was used to isolate genes that are differentially expressed in the TP31 cell line derived from a primary UM compared to UVM. The expression level of selected genes was further validated by microarray, semi-quantitative RT–PCR and western blot analyses.

Results: Analysis of the subtracted libraries revealed that 37 and 36 genes were, respectively, up- and downregulated in TP31 cells compared to UVM. Differential expression of the majority of these genes was confirmed by comparing UM cells with UVM by microarray. The expression pattern of selected genes was analyzed by semi-quantitative RT–PCR and western blot, and was found to be consistent with the SSH findings.

Conclusions: We demonstrated that the SSH technique is efficient to detect differentially expressed genes in UM. The genes identified in this study represent valuable candidates for further functional analysis in UM and should be informative in studying the biology of this tumor.

Uveal melanoma (UM) is a malignant tumor that arises from neural crest-derived melanocytes of the uveal tract of the eye [1]. It is the most prevalent primary cancer of the eye with an annual frequency of 4–7 cases per million of population in North America [1]. This ocular tumor not only has the capacity to destroy vision but can also metastasize and ultimately cause death in up to half of patients diagnosed with this type of cancer. Despite chemotherapy, the metastatic disease is fatal, usually within a few months of diagnosis [1].

Carcinogenesis occurs as an accumulation of molecular events involving disruption of cell cycle and apoptotic control, as well as increased aneuploidy leading ultimately to malignant transformation and dissemination of tumor cells. In the past decade, many details of the pathogenesis of UM have emerged, e.g., the gene-expression signatures with prognostic significance, as well as guanine nucleotide-binding proteins alpha-q and alpha 11 (GNAQ/GNA11) and BRCAl associated protein-1 (BAP1) mutations [2-5]. Despite these discoveries, a better insight into tumor progression of UM primary tumors remains of utmost importance to identify new therapeutic targets. One way to better understand the malignant transformation of cells is to determine which genes are differentially expressed between primary tumors and normal melanocytes.

The suppressive subtractive hybridization (SSH) technique, a combination of subtraction and kinetic enrichment coupled to subsequent amplification, increases the representation of rare mRNAs, which enables to compare two different populations of mRNAs and to obtain clones of genes that are differentially expressed in the population of interest [6,7]. This technique has proven to be useful in identifying tissue-specific and less abundant transcripts as it can achieve over a 1,000 fold enrichment for differentially expressed cDNA populations [6,8]. Here, we describe the identification of 73 genes differentially expressed in primary UM using the SSH technique. Some of these genes are likely involved in malignant transformation and should be informative in studying the biology of UM.

METHODS

This study followed the principles of the Declaration of Helsinki and was approved by our institutional human experimentation committee. Written informed consent was obtained from the enucleated subjects.

Tissue collection and cell culture: The TP31 cell line is derived from a mixed epitheloid-spindle primary UM tumor of a 62-year-old patient that died of liver metastases (Table 1) [9]. This cell line does not have mutations in GNAQ or GNA11 and was cultured in DMEM/F12 medium (Gibco BRL, Burlington, ON) supplemented with 10% FBS (Gemini;
NorthBio, Toronto, ON) under 5% CO2. Normal uveal melanocytes (UVM) were grown from human donor eyes provided by the Banque d’Yeux Nationale (CHUL, Québec, QC), according to the procedure described by Hu et al. [10].

Samples of UM primary tumors were collected at the time of enucleation (Table 1) and were either immediately stored at −80 °C in Tri-Reagent for RNA extraction (Sigma-Aldrich, Oakville, ON) or grown in tissue culture for less than 9 passages [9]. Tumors were classified according to a modification of the Callender’s classification [11].

suppressible subtractive hybridization (SSH): Total RNA derived from both the TP31 cell line and UVM (pool of 18 donors) was extracted with the RNeasy kit (Qiagen, Mississauga, ON) and mRNA was isolated with the Oligotex mRNA kit (Qiagen) according to the manufacturer’s instructions. cDNA was synthesized using the SMART PCR cDNA Synthesis kit (Clontech Laboratories, Mountain View, CA). Two SSH libraries were then performed between the TP31 cell line and UVM (a forward subtraction named “TP31 cell line subtracted library” and a reverse one named “UVM subtracted library”) using the PCR-Select cDNA Subtraction kit (Clontech Laboratories) according to the procedure described by Diatchenko et al. [7]. In the forward subtraction, the TP31 cell line was used as the tester and UVM as the driver (TP31 cell line subtracted library) whereas the UVM were used as the tester and the TP31 cell line as the driver in the reverse subtraction (UVM subtracted library, which corresponds to downregulated genes in the TP31 cell line). To evaluate the efficiency of the cDNA subtraction, the expression level of actin and endothelin receptor type B (EDNRB; Table 2) was monitored by RT–PCR in subtracted cDNA and unsubtracted cDNA. Aliquots of subtracted and unsubtracted cDNAs were removed from each reaction after 18, 23, 28, and 33 cycles and compared by agarose gel electrophoresis.

Cloning, differential screening, sequencing and analysis of the subtracted cDNAs: The PCR products of the SSH libraries were purified (NucleoSpin Extract kit; Clontech Laboratories) and then inserted into the T/A cloning vector pGEM-T Easy (Promega, Madison, WI). Individual transformants carrying subtracted cDNA fragments were isolated from white colonies and used for differential screening (PCR-Select Differential Screening kit; Clontech Laboratories) to eliminate false positives, according to the manufacturer’s instructions. PCR fragments of the positive clones were isolated with QIAquick PCR Purification kit (Qiagen) and then sequenced using Nested PCR Primers 1 and 2R (Clontech Laboratories) with an automated DNA sequencer (ABI Prism model 3900; Applied Biosystems, Foster City, CA). DNA sequencing of positive clones was performed by the Plateforme de séquençage et de génotypage.
Evaluation of subtraction efficiency: Successful SSH should decrease housekeeping gene transcripts and enrich tissue-specific gene transcripts [6]. A reduction of actin mRNA expression can be observed in the TP31 subtracted library compared to the unsubtracted TP31 cDNA. Indeed, the actin amplicon can be observed after 23 cycles of amplification in the subtracted library compared to 18 cycles for the unsubtracted population (Figure 1A). A similar reduction of actin mRNA expression was observed in the UVM subtracted library (Figure 1B). As a positive control for the enrichment of differentially expressed genes, EDNRB, a melanocytic lineage marker was amplified. EDNRB amplicon can be observed after 18 cycles in the UVM subtracted library compared to 33 cycles for the unsubtracted population (Figure 1C). These data demonstrate successful subtractions, with significant reduction of actin abundance and significant enrichment of EDNRB, 5 cycles corresponding roughly to a 20-fold cDNA concentration difference.

Comparison of mRNA profiles between uveal melanoma and normal uveal melanocytes using SSH: The analysis of the TP31 cell line subtracted library (UM upregulated genes) showed that 58 positive clones corresponded to 37 genes when taking the redundancy into account (Table 3). 57% of these genes were previously associated with cancer (highlighted in bold in Table 3). The most highly represented genes in this subtracted library were anillin (ANLN) and the cytoskeleton associated protein 5 (CKAP5). Analysis of the UVM subtracted library (UM downregulated genes) showed that 54 positive clones corresponded to 36 genes when taking the redundancy into account (Table 4). Among these genes, 55% were previously found to be downregulated in cancer (highlighted in bold in Table 4). The most highly represented genes in the UVM subtracted library were actin gamma 1 (ACTG1), alpha-2-macroglobuline (A2M), cathepsin K (CTSK), and proteolipid protein 1 (PLP1). Comparison with microarray data of the previously published transcriptome of UVM [12] confirmed an upregulation of 70% of the genes identified in the TP31 cell line subtracted library and a downregulation of 81% of the genes identified in the UVM subtracted library (Table 3 and Table 4, last column). The most represented biologic processes were associated to cell division and metabolism for the upregulated genes, while they were linked to differentiation and G-protein signaling for the downregulated genes.

Validation of selected up- and downregulated genes by semi-quantitative RT–PCR and western blot: Semi-quantitative RT–PCR analyses were performed to compare the expression of the upregulated genes acidic nuclear phosphoprotein 32 member E (ANP32E), CKAP5, and denticelloid homolog (DIL) from the TP31 cell line subtracted library (Figure 2A), as well as the downregulated genes CTSK, methylthioadenosine phosphorylase (MTAP), and testis-specific protein-like 1 y-encoded (TSPYL5) from the UVM subtracted library (Figure 2B) between the TP31 cell line, UM primary tumors, and UVM. These genes were chosen for their redundancy in the SSH libraries and/or their implication in malignant melanoma or other cancers, after microarray validation. These analyses showed identical expression patterns as those revealed by the SSH technique, indicating that the SSH data were accurate. Indeed, no band could be seen in the UVM for the upregulated genes (Figure 2A). In addition, no band could be observed in the TP31 cell line and UM primary tumors for the downregulated genes (Figure 2B).
We next examined both mRNA and protein expression of ANLN and TYRP1 between TP31 cell line, UM primary tumors, and UVM (Figure 3). Neither mRNA nor protein could be detected for ANLN in UVM compared to TP31 and some primary tumors (Figure 3A). TYRP1 mRNA and protein level were greatly decreased in TP31 mRNA and protein compared to UVM (Figure 3B). In addition, PPP3CA mRNA or protein was not detected in UVM.

Figure 1. Evaluation of the subtraction efficiency by PCR using the housekeeping gene actin and the melanocyte marker EDNRB. A: Reduction of actin expression in the TP31 subtracted library compared to unsubtracted TP31 cDNA. B: Reduction of actin expression in the UVM subtracted library compared to unsubtracted UVM cDNA. C: Enrichment of EDNRB expression in the UVM subtracted library compared to unsubtracted UVM cDNA. Samples were taken after 18, 23, 28, and 33 PCR cycles.
| Gene                                                                 | Chromosomal location | GenBank accession | Biological process   | Redundancy | Microarray fold-change UM/UVM |
|----------------------------------------------------------------------|----------------------|-------------------|----------------------|------------|-------------------------------|
| Acidic (leucine-rich) nuclear phosphoprotein 32 member E (ANP32E)    | 1q21.2               | NM_030920         | Apoptosis            | 1          | 1.59                          |
| Alkyglycerone phosphate synthase (AGPS)                              | 2q31.2               | NM_003569         | Lipid metabolism     | 2          | 2.85                          |
| Anillin actin binding protein (ANLN)                                 | 7p14                 | NM_018685         | Cell division        | 4          | 2.69                          |
| ATP synthase H+ transporting mitochondrial F0 complex subunit G (ATP5L)| 1q13.3               | NM_006476         | ATP synthesis         | 1          | 11.20                         |
| Calumenin (CALU)                                                     | 7q21.1               | NM_001219         | Calcium ion binding   | 2          | 1.43                          |
| Chromosome 6 open reading frame 211 (C6orf211)                      | 6q25.1               | NM_024573         | Unknown               | 2          | 1.72                          |
| Chromosome 6 open reading frame 62 (C6orf62)                        | 6p22.3               | NM_039939         | Unknown               | 1          | 0.43                          |
| Chromosome 7 open reading frame 64 (C7orf64)                        | 7q21.2               | NM_032120         | Unknown               | 2          | 1.53                          |
| Cytoskeleton associated protein 5 (CKAP5)                            | 11p11.2              | NM_014756         | Cell division         | 5          | 4.13                          |
| Denticlesess homolog (DTL)                                          | 1q32                 | NM_016448         | Protein ubiquitination| 1          | 3.79                          |
| Family with sequence similarity 126 member B (FAM126B)              | 2q33.1               | NM_173822         | Unknown               | 1          | 1.28                          |
| Family with sequence similarity 35 member A (FAM35A)                | 14q23.2              | NM_019054         | Unknown               | 1          | 1.02                          |
| Family with sequence similarity 63 member B (FAM63B)                | 15q21.3              | NM_001040450      | Unknown               | 1          | 0.92                          |
| Glutamate-ammonia ligase (GLUL)                                     | 1q31                 | NM_002065         | Cell proliferation    | 1          | 1.65                          |
| HEAT repeat containing 5A (HEATR5A)                                  | 14q12                | NM_015473         | Unknown               | 2          | 1.63                          |
| Histone deacetylase 3 (HDAC3)                                       | 7p31                 | NM_003833         | Chromatin modification| 1          | 3.03                          |
| Human T-cell leukemia virus type 1 binding protein 1 (TAX1BP1)       | 7p15                 | NM_006024         | Apoptosis             | 1          | 2.03                          |
| Integrin alpha 6 subunit (ITGA6)                                    | 2q31.1               | NM_00210          | Cell adhesion         | 2          | 1.68                          |
| Interleukin 1 receptor antagonist (IL1RN)                            | 1q24.2               | NM_173842         | Inflammatory response | 5          | 1.71                          |
| KIAA0218                                                            | 3p14.2               | NM_001009899      | G-protein signaling   | 1          | 1.81                          |
| Melanocortin 3 receptor (MC3R)                                      | 2q33.2               | NM_019888         | Melanocyte differentiation | 2          | 0.48                          |
| Microphthalmia-associated transcription factor (MITF)                | 3p14.2               | NM_198159         | Melanocyte differentiation | 2          | 0.48                          |
| Multiple coagulation factor deficiency protein 2 (MCFD2)            | 2p12                 | NM_139279         | Vesicle-mediated transport | 1          | 1.37                          |
| MutL homolog 3 (MLH3)                                                | 14q24.3              | NM_014381         | DNA repair            | 2          | 1.43                          |
| Oligosaccharyltransferase complex subunit (OSTC)                     | 4q25                 | NM_021227         | Protein glycosylation | 1          | 4.31                          |
| Peroxisome proliferator-activated receptor gamma coactivator 1 (PPARGC1) | 4p15.1              | NM_013261         | Cellular respiration  | 1          | 0.51                          |
| Pleckstrin homology domain containing family A member 8 (PLEKHA8)    | 7p21-p11.2           | NM_032639         | Transport protein    | 1          | 1.38                          |
| Potassium voltage-gated channel, Shab-related subfamily member 1 (KCNB1) | 20q13.2             | NM_004975         | Potassium ion transport | 1          | 1.84                          |
| Proteasome 26S subunit non-A (PSMD2)                                 | 3p21.1               | NM_002608         | Protein ubiquitination| 1          | 1.40                          |
| Proteasome maturation protein (POMP)                                | 1q21.3               | NM_015932         | Proteasome assembly  | 1          | 3.16                          |
| Protein phosphatase 3 catalytic subunit alpha isozyme (PPP3CA)       | 4q24                 | NM_00944          | Protein phosphorylation| 1          | 1.51                          |
| Required for meiotic nuclear division 5 homolog A (RMN5A)           | 3p14.2               | NM_027180         | Cell division         | 1          | 1.77                          |
| Topoisomerase (DNA) II alpha (TOP2A)                                 | 17q21-q22            | NM_010067         | DNA replication       | 1          | 19.52                         |
| Translocase of inner mitochondrial membrane 17 homolog A (TIMM17A)  | 1q21.1               | NM_006335         | Mitochondrial protein transport | 1          | 1.63                          |
| Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta polypeptide (YWHAH) | 20q13.1            | NM_003404         | Ras signal transduction | 1          | 4.00                          |
| Vaccinia related kinase 1 (VRK1)                                    | 14q32                | NM_003384         | Protein phosphorylation| 2          | 6.53                          |
| Zinc finger, HIT-type containing 6 (ZNHIT6)                         | 1p22.3               | NM_017653         | Ribosome biogenesis   | 1          | 3.89                          |

*Considered validated if the UM/UVM fold-change was >1.5. Genes highlighted in bold were previously shown to be upregulated in cancer.
| Gene                                      | Chromosomal location | GenBank accession# | Biological process                  | Redundancy | Log2 UM/UVM* |
|-------------------------------------------|----------------------|--------------------|-------------------------------------|------------|--------------|
| Actin gamma 1 (ACTG1)                     | 17q25.3              | NM_001614          | Motility                            | 3          | −86.7        |
| A kinase (PRKA) anchor protein 12 (AKAP12)| 6q25.3               | NM_005100          | G-protein-signaling                | 2          | −1.91        |
| Alpha-2-macroglobuline (A2M)              | 12p13.31             | NM_000014          | Cytokine transport                  | 3          | −44.4        |
| Cathepsin K (CTSK)                       | 1q21                 | NM_000396          | Proteolysis                         | 3          | −106.5       |
| Chromosome 1 open reading frame 124 (C1orf124)| 1q42                  | NM_052018          | DNA repair                          | 2          | −60          |
| Dynein cytoplasmic 1 light intermediate chain 2 (DYNC1LI2)| 16q22.1              | NM_006334          | Endosome transport                  | 1          | −88.9        |
| E74-like factor 1 (ets domain transcription factor) (ELF1) | 13q13               | NM_172373          | Transcription                       | 1          | −1.83        |
| Endothelin receptor type B (EDNRB)        | 13q22                | NM_000115          | Melanocyte differentiation          | 1          | −15          |
| Epithelial membrane protein 1 (EMP1)      | 12p12.3              | NM_001423          | Epithelial cell differentiation     | 1          | −148.8       |
| Formin binding protein 4 (FNBP4)          | 11p11.2              | NM_015308          | Unknown                             | 1          | −7.82        |
| Glycoprotein (transmembrane) nmb (GPNMB)  | 7p15                 | NM_002510          | Melanocyte differentiation          | 1          | −84.5        |
| Guanine nucleotide binding protein alpha inhibiting polypeptide 3 (GNAI3) | 1p13                  | NM_006496          | G-protein signaling                | 2          | −0.62        |
| Guanine nucleotide binding protein gamma 11 (GNG11) | 7q21                 | NM_004126          | G-protein signaling                | 1          | −6.56        |
| Heterochromatin protein 1 binding protein 3 (HP1BP3) | 1p36.12              | NM_016287          | Nucleosome assembly                 | 1          | −2.37        |
| Importin 7 (IPO7)                        | 11p15.4              | NM_006391          | Protein transport                   | 2          | −0.64        |
| Junction mediating and regulatory protein p53 cofactor (JMY) | 5q14.1               | NM_152405          | Apoptosis                           | 1          | −1.68        |
| Leucine rich repeat containing 39 (LRRC39) | 1p21.2               | NM_144620          | Apoptosis                           | 1          | −3.90        |
| Methylthioadenosine phosphorylase (MTAP)  | 9p21                 | NM_002451          | Apoptosis                           | 1          | −2.45        |
| Nerve growth factor receptor associated protein 1 (NGFRAP1) | Xq22.2                | NM_206915          | Apoptosis                           | 1          | −2.20        |
| Potassium channel tetramerisation domain containing 18 (KCTD18) | 2q33.1              | NM_152387          | Potassium ion transport             | 1          | −1.33        |
| Potassium inwardly-rectifying channel subfamily J member 13 (KCNJ13) | 2q37                 | NM_002242          | Potassium ion transport             | 2          | −21.9        |
| Proteolipid protein 1 (PLP1)             | Xq22                 | NM_000533          | Glial cell differentiation          | 4          | −5.78        |
| Rho-related BTB domain-containing protein 3 (RHOBTB3) | 5q15                  | NM_014899          | Protein transport                   | 4          | −5.78        |
| Ribosomal protein S6 kinase polypeptide 1 (RPS6KC1) | 1q41                 | NM_012424          | Protein phosphorylation             | 1          | −1.64        |
| SLIT and NTRK-like family member 2 (SLITRK2) | Xq27.3              | NM_032539          | Axonogenesis                        | 1          | −2.51        |
| SRY (sex determining region Y)-box 4 (SOX4) | 6p22.3               | NM_000533          | Protein glycosylation               | 2          | −2.51        |
| Testis-specific protein-like 1, y-encoded (TSPYL5) | Xq22.2               | NM_05767           | Protein glycosylation               | 1          | −2.14        |
| Tyrosinase-related protein 1 (TYRP1)      | 9p23                 | NM_000550          | Melanocyte differentiation          | 1          | −397         |
| Ubiquitin-conjugating enzyme E2H (UBE2H) | 7q32                  | NM_003344          | Protein ubiquitination              | 1          | −2.32        |
| WW domain binding protein 5 (WBP5)        | Xq22.2               | NM_016303          | Unknown                             | 1          | −2.54        |
| Zinc finger AN1-type domain 5 (ZFN5)     | 9q21                 | NM_006007          | Development                        | 2          | −0.61        |

*Considered validated if the UM/UVM fold-change was <-1.5. Genes highlighted in bold were previously shown to be downregulated in cancer.
compared to TP31 and primary tumors (Figure 4). Moreover, we identified a new splice variant of PPP3CA in the TP31 cell line as well as in the primary tumors. This shorter amplicon was not expressed by the UVM (Figure 4A, lower band). The sequencing of this amplicon allowed the identification of a new splice variant of PPP3CA lacking exon 2 (PPP3CAΔ2).

Western blots were performed to confirm the existence of a splice variant of the PPP3CA protein using an antibody raised against exon 1 to assess the expression of both the native protein and the splice variant lacking exon 2. As can be seen in Figure 4B (left panel), two protein products were detected at 51- and 59-kDa in the extracts prepared from both the TP31 cell line and a pool of UM primary tumor protein extracts, but not in UVM. When using several UM primary tumors separately, some expressed both the native PPP3CA protein and the splice variant, while others expressed only the splice variant (Figure 4B, right panel).

**DISCUSSION**

Only a few oncogenes involved in the development of UM primary tumors have been discovered until now. This study was undertaken to identify additional genes that could be required for malignant transformation of melanocytes by preparing subtracted libraries using normal UVM and the UM cell line TP31. The sequencing of upregulated cDNAs from the TP31 cell line subtracted library and downregulated...
cDNAs from the UVM subtracted library has resulted in the identification of 73 genes differentially expressed by UM.

Many genes found to be upregulated in the TP31 cell line subtracted library were previously associated with cancer, including \textit{ANLN} and \textit{PPP3CA}. ANLN is an actin binding protein that can associate with septins and is involved in cytokinesis [15]. Several studies have demonstrated an overexpression of \textit{ANLN} in cancer such as in several of the UM tumors assayed in the present study. Indeed, Hall et al. assessed \textit{ANLN} expression in several human tissue samples and cell lines by microarray analyses and demonstrated that the median level of \textit{ANLN} expression was higher in tumors than in normal tissues and correlated with the metastatic potential of these tumors [16]. Moreover, \textit{ANLN} overexpression was shown to increase levels of active RhoA and subsequently cell motility [16]. Therefore, given that increased genomic instability is a feature of metastatic UM tumors [1], \textit{ANLN} overexpression could create defects in cytokinesis leading to binucleation and genomic instability.

Calcineurin is a protein phosphatase regulating the Ca\(^{2+}\)/calmodulin complex, formed by a catalytic A subunit (\textit{PPP3CA}) and a regulatory B subunit [17]. Whereas interest was previously confined to its activity in immune response, calcineurin is now becoming recognized as a predominant participant in oncogenesis [18]. Indeed, the Ca\(^{2+}\)/calcineurin/nuclear factor of activated T-cells (NFAT) signaling pathway influences different aspects of tumor biology, such as stimulation of angiogenesis through upregulation of vascular endothelial growth factor (VEGF), tumor cell proliferation through upregulation of myelocytomatosis oncogene (MYC), and tumor cell migration through cyclooxygenase-2 (COX-2) [18]. Native \textit{PPP3CA} contains five distinct domains: the NH\(_2\)-terminal, the catalytic, the B-subunit binding, the calmodulin-binding and the auto-inhibitory domains [17]. Three variants were identified previously and one splice variant showed no phosphatase activity, but was able to

Figure 4. \textit{PPP3CA} expression in UM. A: The expression level of \textit{PPP3CA} mRNA was measured by semi-quantitative RT–PCR in the TP31 cell line, UM primary tumors (Tumors), and UVM. B: The expression level of the \textit{PPP3CA} protein was measured by western blot in the TP31 cell line, UVM, and UM primary tumors (left panel: pool of protein extracts from UM primary tumors; right panel: individual UM primary tumors). A new splice variant was detected, which lacks parts of the NH\(_2\)-terminal and catalytic domains after the deletion of exon 2 (\textit{PPP3CAΔ2}). The 18S rRNA was used as internal control of amplification (489 bp). Actin was used as a protein loading control. Data are representative of three independent experiments.
stimulate the phosphatase activity of the native protein, thus rendering PPP3CA more calcium-sensitive [19].

In the present study, we reported the expression of a novel PPP3CA splice variant in primary UM cells that lacks part of the NH2-terminus and catalytic domains (PPP3CA Δ2; GenBank#AY904364; Figure 4). Further biochemical analysis will be necessary to determine whether or not the catalytic activity of this new variant is altered.

Among the genes found to be downregulated in the UVM subtracted library, several were previously associated with melanoma, such as melanocytic markers TYRP1, EDNRB, MTAP, and sex determining region Y box 4 (SOX4; Table 4). Indeed, the expression of TYRP1 was inversely correlated with tumor stage in malignant melanoma [20]. A decreased expression of EDNRB was previously associated with early metastasis and short survival in UM [21]. A tissue microarray study in malignant melanoma demonstrated a significant reduction of MTAP in melanomas and metastases compared with nevi [22]. In addition, SOX4 expression was reduced in metastatic malignant melanoma compared with dysplastic nevi and primary melanoma. SOX4 downregulation was correlated with a poor prognosis and SOX4-depleted melanoma cells showed enhanced invasion and migration [23].

SSH technique was previously used in efforts to identify genes that were differentially expressed in UM [21,24,25]. One study was aiming to identify genes involved in the development of metastases [21] whereas the other studies were rather aiming to identify genes that are involved in malignant transformation of melanocytes [24,25]. Only a very small number of genes were reported by these studies as a result of the analysis of their subtracted library [21,24,25]. As a consequence, an extensive comparison between our results and their data could not be performed. Among the four genes they reported, namely the cysteine-rich protein 61 (CYR61) and tissue factor (also called coagulation factor III), EDNRB and the AXL receptor tyrosine kinase (AXL), only EDNRB was identified in our UVM subtracted library [21,24,25].

One limitation of the present study is the use of only one primary UM cell line for the preparation of the SSH libraries. However, the validation of the SSH list of genes by microarray, semi-quantitative RT–PCR and western blot with primary tumor samples compensated for the use of only the TP31 cell line as starting material. It is noteworthy that the TP31 cell line is devoided of the GNAQ/GNA11 mutations and that, consequently, the genes reported in the present study could allow to establish a new mechanism for early gene expression changes leading to malignant transformation and proliferation of uveal melanocytes. Consistent data have been obtained when comparing the SSH results with microarray data and RNA/protein extracts of primary UM tumors, suggesting that UM cell lines could represent good models for such analyses given the limited availability of primary UM tumor samples. Studying the function of these genes and their biologic pathways may lead to the development of new therapeutic options.

ACKNOWLEDGMENTS
The authors would like to thank Dr. Dan Bergeron and Mrs. Marcelle Giasson for clinical follow-up data, and Drs. Daniel O. Black and Yvonne Molgat for the UM tumor samples. They are also grateful to the nurses Louise Monroe and Sylvie Marcoux from the Clinique des tumeurs oculaires du service d’ophtalmologie du CHUL for the recruitment of patients, as well as the Banque d’Yeux Nationale for providing human globes. The Banque d’Yeux Nationale is partly supported by the Réseau de Recherche en Santé de la Vision. The authors are indebted to the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Réseau de Recherche en Santé de la Vision for their financial support. S.L. and C.B.L. were holding scholarships from the Canadian Institutes of Health Research (CIHR) as well as from the Fonds de la Recherche en Santé du Québec (FRSQ). F.V. and M.G. were supported by scholarships from the CIHR and the FRSQ, respectively. M.M. was supported by an Undergraduate Student Research Award from NSERC.

REFERENCES
1. Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol 2008; 4:629-36. [PMID: 18922120]
2. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010; 12:461-8. [PMID: 20413675]
3. Van Raamsdonk CD, Bezrookove V, Green G, Bauer L, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457:599-602. [PMID: 19078957]
4. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel G, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O’Brien J, Bastian BC. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363:2191-9. [PMID: 21083380]
5. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcoock AM. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330:1410-3. [PMID: 20151595]
6. Velculescu VE, Middlen SL, Zhang L, Lash AE, Yu J, Rago C, Lal A, Wang CJ, Beaudry GA, Ciriello KM, Cook BP, Dufault MR, Ferguson AT, Gao Y, He TC, Hermeking H, Hirlindo SK, Hwang PM, Lopez MA, Luderer HF, Mathews B, Petroziello JM, Polyak K, Zawel L, Kinzler KW. Analysis of human transcriptomes. Nat Genet 1999; 23:387-8. [PMID: 10581018]
7. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, Lukyanov S, Lukyanov K, Gurskaya N, Sverdlov ED, Siebert PD. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-
8. Wan JS, Sharp SJ, Poirier GM, Wagaman PC, Chambers J, Pyati J, Hom YL, Galindo JE, Huvor A, Peterson PA, Jackson MR, Erlander MG. Cloning differentially expressed mRNAs. Nat Biotechnol 1996; 14:1685-91. [PMID: 9634852]

9. Beliveau A, Berube M, Rousseau A, Pelletier G, Guerin SL. Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma. Invest Ophthalmol Vis Sci 2000; 41:2363-72. [PMID: 10892885]

10. Hu DN, McCormick SA, Ritch R, Pelton-Henrion K. Studies of human uveal melanocytes in vitro: isolation, purification and cultivation of human uveal melanocytes. Invest Ophthalmol Vis Sci 1993; 34:2210-9. [PMID: 8505203]

11. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983; 96:502-9. [PMID: 6624832]

12. Landreville S, Vigneault F, Bergeron M, Leclerc S, Gaudreault M, Morcos M, Mouriaux F, Salesse C, Guérin SL. Suppression of 5 gene expression is closely related to the tumorigenic properties of uveal melanoma cell lines. Pigment Cell Melanoma Res 2011.

13. Proulx S, Landreville S, Guerin SL, Salesse C. Integrin alpha5 expression by the ARPE-19 cell line: comparison with primary RPE cultures and effect of growth medium on the alpha5 gene promoter strength. Exp Eye Res 2004; 79:157-65. [PMID: 15325562]

14. Zaniolo K, Desnoyers S, Leclerc S, Guerin SL. Regulation of poly(ADP-ribose) polymerase-1 (PARP-1) gene expression through the post-translational modification of Sp1: a nuclear target protein of PARP-1. BMC Mol Biol 2007; 8:96. [PMID: 17961220]

15. Piekný AJ, Maddox AS. The myriad roles of Anillin during cytokinesis. Semin Cell Dev Biol 2010; 21:881-91. [PMID: 20732437]

16. Hall PA, Todd CB, Hyland PL, McDade SS, Grabsch H, Dattani M, Hillan KJ, Russell SE. The septin-binding protein anillin is overexpressed in diverse human tumors. Clin Cancer Res 2005; 11:6780-6. [PMID: 16203764]

17. Rusnak F, Mertz P. Calcineurin: form and function. Physiol Rev 2000; 80:1483-521. [PMID: 11015619]

18. Buchholz M, Ellenrieder V. An emerging role for Ca2+/calcineurin/NFAT signaling in cancerogenesis. Cell Cycle 2007; 6:16-9. [PMID: 17245111]

19. Reuter A, Mi J, Sehram S, Ludolph AC, Volkel H. A novel calcineurin splice variant that modifies calcineurin activity. Eur J Biochem 2001; 268:5955-60. [PMID: 11722584]

20. Bolander A, Aarnslöö M, Strömberg S, Ponten F, Hesselius P, Uhlen M, Bergqvist M. The protein expression of TRP-1 and galexin-1 in cutaneous malignant melanomas. Cancer Genomics Proteomics 2008; 5:293-300. [PMID: 19287070]

21. Smith SL, Damato BE, Scholes AG, Nunn J, Field JK, Heighway J. Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. Br J Cancer 2002; 87:1308-13. [PMID: 12439722]

22. Meyer S, Wild PJ, Vogt T, Bataille F, Ehret C, Gantner S, Landthaler M, Klinkhammer-Schalke M, Hofstaedter F, Bosscherhoff A. Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma. Exp Dermatol 2010; 19:e251-7. [PMID: 20500769]

23. Jafarnejad SM, Wani AA, Martinka M, Li G. Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion. Am J Pathol 2010; 177:2741-52. [PMID: 20952589]

24. Walker TM, Van Ginkel PR, Gee RL, Ahmadi H, Subramanian L, Ksander BR, Meisner LF, Albert DM, Polans AS. Expression of angiogenic factors Cyr61 and tissue factor in uveal melanoma. Arch Ophthalmol 2002; 120:1719-25. [PMID: 12470148]

25. van Ginkel PR, Gee RL, Shearer RL, Subramanian L, Walker TM, Albert DM, Meisner LF, Varnum BC, Polans AS. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res 2004; 64:128-34. [PMID: 14729616]